Boston Scientific Corporation (ETR:BSX)

Germany flag Germany · Delayed Price · Currency is EUR
90.80
+0.20 (0.22%)
Last updated: May 7, 2025
36.54%
Market Cap 135.74B
Revenue (ttm) 16.24B
Net Income (ttm) 1.88B
Shares Out n/a
EPS (ttm) 1.27
PE Ratio 72.20
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 229
Open 90.80
Previous Close 90.60
Day's Range 90.80 - 90.80
52-Week Range 62.00 - 105.00
Beta n/a
RSI 54.38
Earnings Date Apr 23, 2025

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1979
Employees 53,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.

Financial numbers in USD Financial Statements

News

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today

Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a marke...

6 days ago - Benzinga

Boston Scientific announces upcoming investor conference schedule

MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

6 days ago - PRNewsWire

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

8 days ago - Seeking Alpha

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints

Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...

13 days ago - PRNewsWire

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

Boston Scientific Corporation (NYSE: BSX) posted better-than-expected earnings for the first quarter on Wednesday . The company reported first-quarter 2025 revenues of $4.66 billion, beating the cons...

13 days ago - Benzinga

Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results

Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.

13 days ago - Benzinga

IBD Stock Of The Day, Boston Scientific, A 'Top Decile' Player, Is Eyeing Two Entries

Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.

13 days ago - Investor's Business Daily

Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ETCompany ParticipantsJon Monson - Senior Vice President,...

14 days ago - Seeking Alpha

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition

Boston Scientific Corporation (NYSE: BSX) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion . Sales increased 20.9% on a reported bas...

14 days ago - Benzinga

Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition

Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.

14 days ago - Benzinga

Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire

Shares of Boston Scientific rose sharply Wednesday after the firm posted better-than-expected quarterly results.

14 days ago - Investopedia

Boston Scientific Stock Jets 8% Higher On Solid Quarterly Beat, Hiked Guidance

Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales outlook.

14 days ago - Investor's Business Daily

Boston Scientific raises 2025 profit forecast on strong heart device sales

Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.

14 days ago - Reuters

Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan

MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to ret...

14 days ago - PRNewsWire

Boston Scientific announces results for first quarter 2025

MARLBOROUGH, Mass. , April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported...

14 days ago - PRNewsWire

Earnings Scheduled For April 23, 2025

Companies Reporting Before The Bell • GATX (NYSE: GATX) is estimated to report quarterly earnings at $2.09 per share on revenue of $417.09 million. • First Hawaiian (NASDAQ: FHB) is expected to repo...

14 days ago - Benzinga

Boston Scientific Q1 2025 Earnings Preview

15 days ago - Seeking Alpha

Earnings Preview: Boston Scientific

Boston Scientific (NYSE: BSX) is preparing to release its quarterly earnings on Wednesday, 2025-04-23. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

15 days ago - Benzinga

Stryker, Boston Scientific down as new tariffs impact medtech industry

New US tariffs could disrupt the medtech industry, impacting major companies like Boston Scientific and Stryker. Read more here.

4 weeks ago - Seeking Alpha

Price Over Earnings Overview: Boston Scientific

Looking into the current session, Boston Scientific Inc. (NYSE: BSX) shares are trading at $96.89, after a 3.16% drop. Over the past month, the stock fell by 1.95% , but over the past year, it actual...

4 weeks ago - Benzinga

Goldman Sachs Thinks These Stocks Are ‘Insulated' From a Trade War

Amdocs, Kroger, Bank of New York Mellon and Valvoline lead a list of stocks that Goldman Sachs calls “insensitive” to market volatility.

5 weeks ago - Barrons

Boston Scientific announces conference call discussing first quarter 2025 results

MARLBOROUGH, Mass. , April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter...

5 weeks ago - PRNewsWire